Symic Raises $30 Million for Matrix Biology Program; Looks for China Partners

Symic Bio, a Bay-area matrix biology company, announced a $30 million B financing that included two prominent China-focused investors: HEDA Ventures and Ally Bridge Group. Symic CEO Ken Horne expects these investors will help Symic form China partnerships, according to BioCentury. Symic focuses on therapeutics for the sponge-like extracellular matrix in the body that provides an environment in which cells develop. The company has two drug candidates in clinical development. More details.... Share this with colleagues: // //